[go: up one dir, main page]

WO1993011134A1 - [3H,7H]THIAZOLE[3,4-a]PYRIDINES HAVING ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIVITIES ON THE RESPIRATORY TRACT - Google Patents

[3H,7H]THIAZOLE[3,4-a]PYRIDINES HAVING ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIVITIES ON THE RESPIRATORY TRACT Download PDF

Info

Publication number
WO1993011134A1
WO1993011134A1 PCT/EP1992/002784 EP9202784W WO9311134A1 WO 1993011134 A1 WO1993011134 A1 WO 1993011134A1 EP 9202784 W EP9202784 W EP 9202784W WO 9311134 A1 WO9311134 A1 WO 9311134A1
Authority
WO
WIPO (PCT)
Prior art keywords
bis
group
pyrrolidin
formula
compounds
Prior art date
Application number
PCT/EP1992/002784
Other languages
French (fr)
Inventor
Carmelo A. Gandolfi
Giorgio Long
Giampiero De Cillis
Licia Gallico
Original Assignee
Boehringer Mannheim Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Italia S.P.A. filed Critical Boehringer Mannheim Italia S.P.A.
Publication of WO1993011134A1 publication Critical patent/WO1993011134A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to [3H,7H]thiazole[3,4-a]pyridines, a process for the preparation thereof and pharmaceutical compositions containing them.
  • R is (C 1 -C 4 ) alkyl
  • Ra is hydrogen, C 1 -C 6 alkyl, benzyl
  • Rb is hydrogen or C 1 -C 6 alkyl, or Ra and Rb, together with the nitrogen atom, form a pyrrolidino, piperidino, morpholino, 4- thiomorpholino, (C 1 -C 4 ) alkylpiperazino group;
  • R 2 is a (C 3 -C 7 )cycloalkyl group, ⁇ , ⁇ or ⁇ -pyridyl, optionally substituted phenyl or a bicyclic ring in which a benzene ring is fused to a 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, S and N, said bicyclic ring being linked through the benzene ring;
  • R 3 is a free or salified carboxy group or an alkoxycar- bonyl group
  • D is a 5- or 6-membered heterocycle with 1-3 nitrogen atoms, optionally substituted with 1 or 2 amino, mono- (C 1 -C 6 )alkylamino, mono-(C 3 -C 7 )alkenyl or mono-(C 3 - C 7 ) alkynylamino, di-(C 1 -C 6 )alkylamino, (C 1 -C 6 )alkyl (C 3 - C 7 )alkenylamino, piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl groups.
  • phenyl as herein used, we mean a phenyl ring, containing from 1 to 3 substituents selected from C 1 -C 6 alkyl groups, such as methyl, ethyl, propyl, isopropyl, tert-butyl; (C 1 - C 4 )alkoxy such as methoxy, ethoxy or propoxy; (C 1 - C 4 )alkylthio such as methylthio, ethylthio; phenoxy; 4- hydroxyphenoxy; phenylthio; 4-hydroxyphenylthio; halogen atoms (chlorine, bromine or fluorine); cyano, azido, nitro, amino groups; (C 1 -C 6 )acylamino; trihaloacetylamino such as trifluoroacetylamino; methane- or trifluoromethanesulfonamido; benzene- or para-toly
  • Particularly preferred mono or poly-substituted phenyl groups are those bearing the following substituents: 2-chloro-, 3-chloro-, 4-chloro-, 2,3-dichloro-, 2-fluoro-, 2-fluoro-3-chloro-, 2-nitro-, 3-nitro-, 3- nitro-4-phenoxy-, 4-nitro-, 4-nitro-3-phenoxy-, 2- trif luoromethyl-, 3-trif luoromethyl-, 3-cyano-, 3- methoxy-, 2-amino-, 3-amino-, 4-amino-, 2- methanesulfonamido-, 3-methanesul fonamido-, 4-me- thanesulfonamido-, 3-methanesulfonamido-4-phenoxy-, 4- methanesulfonamido-3-phenoxy-, 4-fluoro-2,3-dichloro-, 3-carboxy-4-hydroxy-, 3-hydroxy-4-carbox
  • R 2 is a (C 3 -C 7 )cycloalkyl group, this is preferably cyclopropyl, cyclopentyl or cyclohexyl.
  • R 1 or R 3 are an alkoxycarbonyl group, this is preferably a (C 1 -C 4 ) alkyl, allyl, propargyl, benzyl, p- methoxybenzyl, benzhydryl, trityl or trichloroethyl ester.
  • R 2 is a bicyclic ring in which a benzene ring is fused with a 5- or 6-membered heterocyclic ring
  • this is preferably benzo-1,3-dioxolane-4-yl, 1,4- benzodioxolane-6-yl, 1,4-benzodioxolane-5-yl, benzo- furan-4-yl, benzofurazan-4-yl.
  • D are: pyridin-2-yl, pyrimidin-4-yl, pyrimidin-2-yl or 1,3,5-triazin-2-yl, optionally substituted with 1 or 2 amino, monoalkylamino (methylamino, ethylamino), 2-pro- penylamino, 2-propynylamino, propylamino, isopro- pylamino or dialkylamino groups such as dime thy lamino, diethylamino, ethyl, 2-propenylamino and the like.
  • D particularly preferred meanings for D are: pyri- din-2-yl, [2,6-bis(diethylamino)pyrimidin-4-yl], [2,6- bis (2-propenylamino)pyrimidin-4-yl], [2,6-bis(ami- no)pyrimidin-4-yl], [2,6-bis(pyrrolidin-1-yl)pyrimidin- 4-yl], [4,6-bis(2-propenylamino)-1,3,5-triazin-2-yl],
  • Particularly preferred compounds (I) are those in which R 1 and R 3 are alkoxycarbonyl groups, particularly methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, 2-propenyloxycarbonyl and tert-butoxycarbonyl groups, or those in which R 1 is a -CONH(CH 2 ) q -NRaRb group, with q, Ra and Rb as defined above, and R 3 is an alkoxycarbonyl group as defined above; R 2 is an optionally substituted phenyl group or a
  • the compounds of formula (la) will be named hereinafter sin-[3H,7H] thiazole[3,4-a]pyridines or simply [3H,7H]thiazole[3,4-a]pyridines.
  • Compounds of formula (lb) will be named anti-[3H,7H]thiazole[3,4- a . pyridines, whereas the diastereomeric mixtures will be indicated as (s,a)-[3H,7H]thiazole[3,4-a]pyridines.
  • optically active compounds (la) will be defined (R)- or (S)-sin-[3H,7H]thiazole[3,4-a]pyridines or simply (R)- or (S)-[3H,7H]thiazole[3,4-a]pyridines; compounds (lb) will be named (R)- or ( S)-anti-[3H,7H]thiazole[3,4- a.pyridines.
  • the compounds of the invention of formula (I) are prepared by a process which consists in reacting a Michael acceptor of formula (Ila) or (llb):
  • Hal is a halogen atom (chlorine, bromine or iodine) and R 4 is a (C 1 -C 4 ) alkyl group, with a 1,4- dihydropyridine of formula (III):
  • an inorganic or organic acid such as hydrochloric, hydrobromic, acetic, camphorsulfonic, mandelic, tartaric, O,O'-dibenzoyltartaric acids.
  • hydrolysis of a carboxyester group to the corresponding carboxy group which in its turn can be transformed into the succinimido ester, the acid chloride, the mixed anhydride or other known reactive carboxy derivatives;
  • conventional hydrolysis procedures comprise, for example, hydrolysis of an allyloxycarbonyl group with ammonium formate, Pd/C and triphenylphosphine; alkali hydrolysis of a methoxy- or ethoxycarbonyl group; hydrolysis of a tert- butoxycarbonyl group with trimethylsilyl iodide, and the like;
  • suitable reducing agents comprise diborane or an alkali or alkaline-earth metal borohydride
  • Michael acceptors of formula (II) are known or they can be prepared with conventional methods; some of them are also commercially available. Particularly, among the compounds of formula (II) the following ones are mentioned: a) propargyl acid esters; b) ⁇ - haloacrylesters (obtained from acryl esters by haloge addition and subsequent dehydrohalogenation).
  • 1,4-Dihydropyridines of formula (III) are know from WO87/00836 (12.02.1987) or they can be prepare according to the methods described in sai international application. Said compounds of formula (III) can be used both in form of racemates and of pure enantiomers.
  • An useful method for the preparation of pure enantiomers of compounds of formula (III) can comprise the optical resolution of the isothiouronium salts with optically active acids, according to the procedure described in EP 90102951.2 (15.02.1990).
  • the compounds of the invention turned out to be effective in preventing and/or decreasing the hyper- reactivity of the respiratory tract and in curing the phlogistic conditions which are related to acute and sub-chronical inflammation of bronchial mucosa.
  • Bronchial hyper-reactivity is a clinical symptom of asthma and it is believed to be a direct consequence of an abnormal and latent contractility and sensitivity of the bronchial mucosa.
  • Bronchial hyper-reactivity can cause acute crisis of asthma after physical practice, and/or after exposure to external stimuli such as the inhalation of fog, pollutants, allergens and autacoids.
  • the bronchial hyper-reactivity conditions may be simulated by an experimental model consisting in the PAF infusion (600 ⁇ g/1) in male guinea-pigs weighing 400-450 g, kept under forced ventilation under urethane and pancuronium bromide anesthesia.
  • PAF which is one of the most important mediators involved in the inflammatory process of the airways, after infusion for 1 hour, causes an hyperreactivity reaction (bronchocostriction) to specific and different substances.
  • the activity of the compounds of the invention, in the considered pharmacological model, is shown by the prevention of the PAF-induced hyper-reactivity, measured as increase of the pulmonary insufflatory pressure (measured according to the modified procedure of Konzett and Rossler, Naun. Schmied, Arch. Exper. Pathol. Pharmacol. 191, 71, 1970).
  • the compounds of the invention which are administered 10 minutes before the PAF administration in dosages which vary between 2 and 50 ⁇ g/kg, demonstrate a protective action which lasts at least 4-6 hours and results in a reduction of the PAF-induced hyperreactivity. Such pharmacological effects are dose-related.
  • the compounds of the invention are also tested according to another experimental model, namely the Late Phase Reaction on sensitized guinea pigs (P.A. Hutson et al., Am. Rev. Respir. Dis. 137; (1988); 548-577.
  • the Late Phase Reaction is characterized by an increase in bronchoalveolar lavage (BAL) of the number of eosi- nophils in guinea pigs sensitized to ovalbumin aerosol.
  • BAL bronchoalveolar lavage
  • the compounds of the invention are effective in reducing the number of eosinophils in BAL, which was made 72 hours after the ovalbumin challenge.
  • the compounds of the invention can be used in human therapy in the treatment of asthmatic and obstructive conditions of the respiratory tract, in the treatment of inflammatory phlogosis.
  • the compounds of the invention will be administered in the form of pharmaceutical compositions which can be prepared with conventional excipients and techniques such as, for example, those described in Remington's Pharmaceutical Sciences Handbook, Mack Pub. Co., N.Y., USA, 17th ed., 1985, adapted for administration by intramuscular, intravenous, oral, aerosol and rectal routes.
  • the daily dose will depend on several factors such as the gravity of the pathology and the condition of the patient: it will normally consist of 1 to 50 mg of a compound of formula (I) for a patient weighing 70 kg, one or more times a day.
  • PREPARATION 2 1 Litre of a sodium bicarbonate saturated aqueous solution is dropped into a suspension of 50 g of (7R)- S-[(6-methyl-5-methoxycarbonyl-3-ethoxycarbonyl-4-(3- nitrophenyl)-1,4-dihydropyridin-2-yl)methyl]isothiouro- nium-D(-)-mandelate in 1 1 of AcOEt, under strong stirring.
  • the aqueous phase is removed, whereas the organic phase is dried over sodium sulfate and solvent is evaporated off under reduced pressure, keeping temperature below 40°C.
  • reaction mixture is added with 0.65 ml of 2-(N-pyrrolidin)ethylamine and stirring is continued for 5 more hours, then the mixture is diluted with 15 ml of water and extracted with AcOEt (3x5 ml). The combined organic extracts are washed with water, dried over sodium sul- fate and solvent is evaporated off under reduced pressure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of formula (I) having antiasthmatic and antiinflammatory activities on the respiratory tract and pharmaceutical compositions containing them.

Description

[3H,7H]THIAZOLE[3,4-a]PYRIDINES HAVING ANTIASTHMATIC
AND ANTIINFLAMMATORY ACTIVITIES ON THE RESPIRA-
TORY TRACT
The present invention relates to [3H,7H]thiazole[3,4-a]pyridines, a process for the preparation thereof and pharmaceutical compositions containing them.
More particularly, the invention relates to compounds of formula (I):
Figure imgf000003_0001
wherein:
R is (C1-C4) alkyl;
is free or salified carboxy group, an alkoxycarbonyl or cyano group or a group of formula -CONH(CH2)q-NRaRb, wherein q is an integer from 2 to 4; Ra is hydrogen, C1-C6 alkyl, benzyl; Rb is hydrogen or C1-C6 alkyl, or Ra and Rb, together with the nitrogen atom, form a pyrrolidino, piperidino, morpholino, 4- thiomorpholino, (C1-C4) alkylpiperazino group;
R2 is a (C3-C7)cycloalkyl group, α, β or α-pyridyl, optionally substituted phenyl or a bicyclic ring in which a benzene ring is fused to a 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, S and N, said bicyclic ring being linked through the benzene ring;
R3 is a free or salified carboxy group or an alkoxycar- bonyl group;
D is a 5- or 6-membered heterocycle with 1-3 nitrogen atoms, optionally substituted with 1 or 2 amino, mono- (C1-C6)alkylamino, mono-(C3-C7)alkenyl or mono-(C3- C7) alkynylamino, di-(C1-C6)alkylamino, (C1-C6)alkyl (C3- C7)alkenylamino, piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl groups.
By "optionally substituted phenyl" as herein used, we mean a phenyl ring, containing from 1 to 3 substituents selected from C1-C6 alkyl groups, such as methyl, ethyl, propyl, isopropyl, tert-butyl; (C1- C4)alkoxy such as methoxy, ethoxy or propoxy; (C1- C4)alkylthio such as methylthio, ethylthio; phenoxy; 4- hydroxyphenoxy; phenylthio; 4-hydroxyphenylthio; halogen atoms (chlorine, bromine or fluorine); cyano, azido, nitro, amino groups; (C1-C6)acylamino; trihaloacetylamino such as trifluoroacetylamino; methane- or trifluoromethanesulfonamido; benzene- or para-tolylsulfonamido; trihalomethyl such as trichloro- or trifluoromethyl; dihalomethoxy such as difluoromethoxy; trifluoromethoxy; free or salified carboxy; (C1-C4) alkoxycarbonyl.
Particularly preferred mono or poly-substituted phenyl groups are those bearing the following substituents: 2-chloro-, 3-chloro-, 4-chloro-, 2,3-dichloro-, 2-fluoro-, 2-fluoro-3-chloro-, 2-nitro-, 3-nitro-, 3- nitro-4-phenoxy-, 4-nitro-, 4-nitro-3-phenoxy-, 2- trif luoromethyl-, 3-trif luoromethyl-, 3-cyano-, 3- methoxy-, 2-amino-, 3-amino-, 4-amino-, 2- methanesulfonamido-, 3-methanesul fonamido-, 4-me- thanesulfonamido-, 3-methanesulfonamido-4-phenoxy-, 4- methanesulfonamido-3-phenoxy-, 4-fluoro-2,3-dichloro-, 3-carboxy-4-hydroxy-, 3-hydroxy-4-carboxy- and combinations thereof.
When R2 is a (C3-C7)cycloalkyl group, this is preferably cyclopropyl, cyclopentyl or cyclohexyl.
When R1 or R3 are an alkoxycarbonyl group, this is preferably a (C1-C4) alkyl, allyl, propargyl, benzyl, p- methoxybenzyl, benzhydryl, trityl or trichloroethyl ester.
When R2 is a bicyclic ring in which a benzene ring is fused with a 5- or 6-membered heterocyclic ring, this is preferably benzo-1,3-dioxolane-4-yl, 1,4- benzodioxolane-6-yl, 1,4-benzodioxolane-5-yl, benzo- furan-4-yl, benzofurazan-4-yl.
Preferred examples of D are: pyridin-2-yl, pyrimidin-4-yl, pyrimidin-2-yl or 1,3,5-triazin-2-yl, optionally substituted with 1 or 2 amino, monoalkylamino (methylamino, ethylamino), 2-pro- penylamino, 2-propynylamino, propylamino, isopro- pylamino or dialkylamino groups such as dime thy lamino, diethylamino, ethyl, 2-propenylamino and the like.
Particularly preferred meanings for D are: pyri- din-2-yl, [2,6-bis(diethylamino)pyrimidin-4-yl], [2,6- bis (2-propenylamino)pyrimidin-4-yl], [2,6-bis(ami- no)pyrimidin-4-yl], [2,6-bis(pyrrolidin-1-yl)pyrimidin- 4-yl], [4,6-bis(2-propenylamino)-1,3,5-triazin-2-yl],
[4,6-bis(diethylamino)-1,3,5-triazin-2-yl], [4,6- bis (pyrrolidin-1-yl)-1,3,5-triazin-2-yl], [3,6-bis (diethylamino)pyridin-2-yl], [3,6-bis(pyrrolidin-1- yl)pyridin-2-yl], [3,6-bis(2-propenylamino)pyridin-2- yl].
Particularly preferred compounds (I) are those in which R1 and R3 are alkoxycarbonyl groups, particularly methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, 2-propenyloxycarbonyl and tert-butoxycarbonyl groups, or those in which R1 is a -CONH(CH2)q-NRaRb group, with q, Ra and Rb as defined above, and R3 is an alkoxycarbonyl group as defined above; R2 is an optionally substituted phenyl group or a
(C3-C7)cycloalkyl group, as defined above; R is methyl.
When in compounds of formula (I) an acid or basic group is present, this can be salified respectively with pharmaceutically acceptable bases or acids. The resulting non toxic salts are included in the invention, as well as the single enantiomers, the racemates and the diastereomers, or the mixtures thereof. Particularly, the compounds of formula (I) contain 2 chiral carbon atoms at the 3 and 7 positions and therefore sin and anti geometries can be defined, corresponding to formulae (la) and (lb):
Figure imgf000007_0001
(Ia)-sin (Ib)-anti
The compounds of formula (la) will be named hereinafter sin-[3H,7H] thiazole[3,4-a]pyridines or simply [3H,7H]thiazole[3,4-a]pyridines. Compounds of formula (lb) will be named anti-[3H,7H]thiazole[3,4- a.pyridines, whereas the diastereomeric mixtures will be indicated as (s,a)-[3H,7H]thiazole[3,4-a]pyridines.
Both compounds of formula (la) and those of formula (lb), which are obtained from racemic dihydropyridines, are the racemic mixtures. The optically active compounds (la) will be defined (R)- or (S)-sin-[3H,7H]thiazole[3,4-a]pyridines or simply (R)- or (S)-[3H,7H]thiazole[3,4-a]pyridines; compounds (lb) will be named (R)- or ( S)-anti-[3H,7H]thiazole[3,4- a.pyridines.
The compounds of the invention of formula (I) are prepared by a process which consists in reacting a Michael acceptor of formula (Ila) or (llb):
Figure imgf000008_0001
wherein Hal is a halogen atom (chlorine, bromine or iodine) and R4 is a (C1-C4) alkyl group, with a 1,4- dihydropyridine of formula (III):
Figure imgf000008_0002
wherein R e R2 are as defined above; R1 ' and R3' have the same meanings as R1 and R3 except for the free or salified carboxy group; R5 is hydrogen or a group of formula C(=NH)-NH2 or C(=NH)-NH2.H+P- wherein P- is the counter-ion of an inorganic or organic acid, such as hydrochloric, hydrobromic, acetic, camphorsulfonic, mandelic, tartaric, O,O'-dibenzoyltartaric acids.
The reaction of compound (II) with compound (III) is usually carried out in an inert solvent and in the presence of a suitable base, to give compounds of formula (Ic):
Figure imgf000008_0003
wherein R, R1', R2, R3 ' and R4 are as defined above, in form of a sin/anti diastereomeric mixture, the sin diastereomer prevailing. The resulting compounds of formula (Ic) can then be subjected to separation of the single diastereomers or they can be transformed into compounds of formula (I), by means of conventional reactions, such as:
a) hydrolysis of a carboxyester group to the corresponding carboxy group, which in its turn can be transformed into the succinimido ester, the acid chloride, the mixed anhydride or other known reactive carboxy derivatives; conventional hydrolysis procedures comprise, for example, hydrolysis of an allyloxycarbonyl group with ammonium formate, Pd/C and triphenylphosphine; alkali hydrolysis of a methoxy- or ethoxycarbonyl group; hydrolysis of a tert- butoxycarbonyl group with trimethylsilyl iodide, and the like;
b) reaction of the acids or of the reactive derivatives thereof obtained according to a) with amines of formula
H2N-(CH2)q-NRaRb;
c) reduction of the free or salified carboxy group or of a corresponding mixed anhydride thereof or of a carboxyester group to primary alcohol (CH2OH); suitable reducing agents comprise diborane or an alkali or alkaline-earth metal borohydride;
d) alcohols obtained according to c) can be converted into the compounds of the invention of formula (I) by reaction with thiocarbonyldiimidazole and subsequently with an amine of formula (IV):
(IV)
Figure imgf000009_0001
e) reduction of the aromatic nitro groups possibly present in compounds of formula (Ic) to give amino groups;
f) acylation of the amino groups obtained according to e) to give the corresponding amides and sulfonamides by reaction with carboxylic, alkylsulfonic or arylsulfonic acid halides or anhydrides;
g) salification and/or separation of optical, geometric or diastereomeric isomers according to conventional methods.
The reaction of compounds of formula (II) and (III) involves the formation of the intermediates of formula (Va) or (Vb):
Figure imgf000010_0001
which can then be cyclized to compounds of formula (Ic) without intermediate isolation.
Michael acceptors of formula (II) are known or they can be prepared with conventional methods; some of them are also commercially available. Particularly, among the compounds of formula (II) the following ones are mentioned: a) propargyl acid esters; b) α- haloacrylesters (obtained from acryl esters by haloge addition and subsequent dehydrohalogenation).
1,4-Dihydropyridines of formula (III) are know from WO87/00836 (12.02.1987) or they can be prepare according to the methods described in sai international application. Said compounds of formula (III) can be used both in form of racemates and of pure enantiomers. An useful method for the preparation of pure enantiomers of compounds of formula (III) can comprise the optical resolution of the isothiouronium salts with optically active acids, according to the procedure described in EP 90102951.2 (15.02.1990).
Piperazines of formula (IV) are described in WO87/01706 (26.03.1987).
The compounds of the invention turned out to be effective in preventing and/or decreasing the hyper- reactivity of the respiratory tract and in curing the phlogistic conditions which are related to acute and sub-chronical inflammation of bronchial mucosa.
Bronchial hyper-reactivity is a clinical symptom of asthma and it is believed to be a direct consequence of an abnormal and latent contractility and sensitivity of the bronchial mucosa.
Bronchial hyper-reactivity can cause acute crisis of asthma after physical practice, and/or after exposure to external stimuli such as the inhalation of fog, pollutants, allergens and autacoids.
The bronchial hyper-reactivity conditions may be simulated by an experimental model consisting in the PAF infusion (600 μg/1) in male guinea-pigs weighing 400-450 g, kept under forced ventilation under urethane and pancuronium bromide anesthesia.
PAF, which is one of the most important mediators involved in the inflammatory process of the airways, after infusion for 1 hour, causes an hyperreactivity reaction (bronchocostriction) to specific and different substances.
The activity of the compounds of the invention, in the considered pharmacological model, is shown by the prevention of the PAF-induced hyper-reactivity, measured as increase of the pulmonary insufflatory pressure (measured according to the modified procedure of Konzett and Rossler, Naun. Schmied, Arch. Exper. Pathol. Pharmacol. 191, 71, 1970).
The compounds of the invention, which are administered 10 minutes before the PAF administration in dosages which vary between 2 and 50 μg/kg, demonstrate a protective action which lasts at least 4-6 hours and results in a reduction of the PAF-induced hyperreactivity. Such pharmacological effects are dose-related.
The compounds of the invention are also tested according to another experimental model, namely the Late Phase Reaction on sensitized guinea pigs (P.A. Hutson et al., Am. Rev. Respir. Dis. 137; (1988); 548-577. The Late Phase Reaction is characterized by an increase in bronchoalveolar lavage (BAL) of the number of eosi- nophils in guinea pigs sensitized to ovalbumin aerosol. The compounds of the invention are effective in reducing the number of eosinophils in BAL, which was made 72 hours after the ovalbumin challenge.
From what has been shown above it is clear that the compounds of the invention can be used in human therapy in the treatment of asthmatic and obstructive conditions of the respiratory tract, in the treatment of inflammatory phlogosis. For the intended therapeutic uses, the compounds of the invention will be administered in the form of pharmaceutical compositions which can be prepared with conventional excipients and techniques such as, for example, those described in Remington's Pharmaceutical Sciences Handbook, Mack Pub. Co., N.Y., USA, 17th ed., 1985, adapted for administration by intramuscular, intravenous, oral, aerosol and rectal routes.
The daily dose will depend on several factors such as the gravity of the pathology and the condition of the patient: it will normally consist of 1 to 50 mg of a compound of formula (I) for a patient weighing 70 kg, one or more times a day.
PREPARATION 1
To a suspension of S-[(6-methyl-5-methoxycarbonyl- 3-ethoxycarbonyl-4-(3-nitrophenyl)-1,4-dihydropyridin- 2-yl)methyl]isothiouronium chloride (20 g) in MeOH (200 ml), methyl propiolate (4.2 ml) and aqueous NaOH (35 %, 10.8 ml) are added in this order under inert gas atmosphere at room temperature and under stirring. After complete dissolution of the reagents, a crystalline precipitate forms which is redissolved by addition of DMF (40 ml). Stirring is continued for 12 more hours, during which a second precipitate forms which is filtered to obtain 14.6 g of methyl 2-(3-(5-methyl-6-metho- xycarbonyl-7-(3-nitrophenyl)-8-ethoxycarbonyl)[3H,7H]- thiazole[3,4-a]pyridinyl)acetate, m.p. 158-160°C.
PREPARATION 2 1 Litre of a sodium bicarbonate saturated aqueous solution is dropped into a suspension of 50 g of (7R)- S-[(6-methyl-5-methoxycarbonyl-3-ethoxycarbonyl-4-(3- nitrophenyl)-1,4-dihydropyridin-2-yl)methyl]isothiouro- nium-D(-)-mandelate in 1 1 of AcOEt, under strong stirring. At the end of the addition, the aqueous phase is removed, whereas the organic phase is dried over sodium sulfate and solvent is evaporated off under reduced pressure, keeping temperature below 40°C.
The residual (7R)-S-[(6-methyl-5-methoxycarbonyl- 3-ethoxycarbonyl-4-(3-nitrophenyl)-1,4-dihydropyridin- 2-yl)methyl]isothioureide (37 g) is dissolved in 150 ml of methanol and quickly added with 9 ml of methyl propiolate, under mechanical stirring and inert gas atmosphere, and immediately after that with 35% aqueous NaOH (11.3 ml). Precipitation of the product takes place nearly immediately. After 15 minutes the reaction mixture is added with 37% hydrochloric acid to acid pH, then the crystalline solid is filtered and dried, to obtain 40.2 g of methyl (7R)-3-[(6-methyl-5-methoxycar- bonyl-3-ethoxycarbonyl-4-(3-nitrophenyl)-1,4-dihydropy- ridin-2-yl)methylthio]acrylate.
To a solution of 40.2 g of methyl (7R)-3-[(6- methyl-5-methoxycarbonyl-3-ethoxycarbonyl-4-(3-nitro- phenyl)-1,4-dihydropyridin-2-yl)methylthio]acrylate in 110 ml of anhydrous DMF, 12.8 ml of 1,8-diazabicy- clo[5.4.0]undec-7-ene (DBU) are added, under stirring and inert gas atmosphere. Stirring is continued for 18 more hours, then the reaction mixture is cooled with water/ice and added with 37% hydrochloric acid to acid pH. The crystalline precipitate is separated by filtra tion, to obtain 35.7 g of methyl (7R)-2-(3-(5-methyl-6- methoxycarbonyl-7-(3-nitrophenyl)-8-ethoxycarbonyl)- [ 3H,7H]thiazole[3,4-a]pyridinyl)acetate, m.p. 126- 128°C.
PREPARATION 3
6.4 g of methyl (7R)-2-(3-(5-methyl-6-methoxycar- bonyl-7-(3-nitrophenyl)-8-ethoxycarbonyl)[3H,7H]thia- zole[3,4-a]pyridinyl) acetate are added under stirring to a suspension of LiBr (3.8 g) and sodium borohydride (1.75 g) in diglyme (10 ml), which has been proviously kept at room temperature for 30 minutes. The reaction mixture is heated to 50°C for one hour, then it is poured into water and acidified with IN hydrochloric acid. After extraction with AcOEt (3x15 ml), the combined or- ganic extracts are washed repeatedly with water (5x20 ml), dried over sodium sulfate and solvent is evaporated off under reduced pressure, to give 4.8 g of (7R)- 2-(3-(5-methyl-6-methoxycarbonyl-7-(3-nitrophenyl)-8- ethoxycarbonyl)[3H,7H]thiazole[3,4-a]pyridinyl)-etha- nol, m.p. 58-62°C, [α]D= -51.9° (c=0.21 in EtOH).
PREPARATION 4
Following the procedure described in preparations 2 and 3, the following 2-([3H,7H]thiazole[3,4- a]pyridin-3-yl)ethanols are prepared:
5-methyl-6-methoxycarbonyl-7-(3-chlorophenyl)-8-ethoxy- carbonyl,
5-methyl-6-methoxycarbonyl-7-cyclohexyl-8-ethoxycar- bonyl,
5-methyl-6-allyloxycarbonyl-7-(3-nitrophenyl)-8-ethoxy- carbonyl,
5-methyl-6-allyloxycarbonyl-7-(3-chlorophenyl)-8-e- thoxycarbonyl,
5-methyl-6-allyloxycarbonyl-7-cyclohexyl-8-ethoxycar- bonyl.
EXAMPLE 1
A solution of 3.5 g of (7R)-2-(3-(5-methyl-6- methoxycarbonyl-7-(3-nitrophenyl)-8-ethoxycarbonyl)- [3H,7H]thiazole[3,4-a]pyridinyl)ethanol in 20 ml of anhydrous THF is added with 1.74 g of thiocarbonyldiimidazole, under stirring and inert gas atmosphere. After 5 hours, a solution of N-[3, 6-bis (diethylamino)pyridin-2-yl]piperazine (2.65 g) in 15 ml of THF is dropped into the reaction mixture, which is left for one more hour under stirring at room temperature, then the reaction mixture is added with 70 ml of water and repeatedly extracted with AcOEt (3x20 ml). The combined organic extracts are washed with water (3x10 ml), dried over sodium sulfate and solvent is evaporated off under reduced pressure. The residue (6.7 g) is purified by silica gel chromatography (200 g of silica; eluent methylene chloride/methanol 98/2) to give 4.3 g of (7R)-N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5- methyl-6-methoxycarbonyl-7-(3-nitrophenyl)-8-ethoxycar- bonyl)[3H,7H]thiazole[3,4-a]pyridinyl)ethoxythiocarbo- nyl)piperazine, m.p. sulfate 169-171°C, [α]D=+4.4° (c-0.2 in EtOH).
EXAMPLE 2
Following the procedure described in example 1, the following (([3H,7H]thiazole[3,4-a]pyridinyl)etho- xythiocarbonyl)piperazines are prepared:
(7R)-N-(2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl)-N--(2- (3-(5-methyl-6-methoxycarbonyl-7-(3-nitrophenyl)-8- ethoxycarbonyl), m.p. sulfate 162-165°C,
N-(4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-N'-(2- (3-(5-methyl-6-methoxycarbonyl-7-(3-nitrophenyl)-8- ethoxycarbonyl), 1H NMR (200 MHz) δ 1.26 (t,3H), 1.95 (m,8H), 2.34 (m,2H), 2.59 (s,3H), 3.55 (m,14H), 3.67 (s,3H), 3.85 (m,2H), 4.14 (m,4H), 4.2 (d,1H), 4.65 (d,1H), 5.18 (s,1H), 5.5 (m,1H), 7.41 (t,1H), 7.6 (d,1H), 8.05 (m,2H),
N-(2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl)-N'-(2-(3-(5- methyl-6-methoxycarbonyl-7-(3-chlorophenyl)-8-ethoxy- carbonyl), 1H NMR (200 MHz) δ 1.25 (t,3H), 1.93 (m,8H), 2.35 (m,2H), 2.6 (s,3H), 3.55 (m,14H), 3.67 (s,3H), 3.85 (m,2H), 4.15 (m,4H), 4.2 (d,1H), 4.65 (d,1H), 4.87 (s,1H), 5.19 (s,1H), 5.51 (m,1H), 7.21 (m,4H),
N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5-me- thyl-6-methoxycarbonyl-7-(3-chlorophenyl)-8-ethoxycar- bonyl), 1H NMR (200 MHz) δ 0.97 (t,6H), 1.1 (t,6H), 1.25 (t,3H), 2.35 (m,2H), 2.6 (s,3H), 2.98 (q,4H), 3.53 (m,10H), 3.68 (s,3H), 3.84 (m,2H), 4.14 (m,4H), 4.22 (d,1H), 4.66 (d,1H), 5.17 (s,1H), 5.51 (m,1H), 6.07 (d,1H), 7.1 (d,1H), 7.22 (m,4H),
N-(4,6-bis(pyrrolidin-l-yl)-l,3,5-triazin-2-yl)-N'-(2- (3-(5-methyl-6-methoxycarbonyl-7-(3-chlorophenyl)-8- ethoxycarbonyl), 1H NMR (200 MHz) δ 1.25 (t,3H), 1.93 (m,8H), 2.36 (m,2H), 2.59 (s,3H), 3.53 (m,14H), 3.65
(s,3H), 3.85 (m,2H), 4.13 (m,4H), 4.22 (d,1H), 4.67 (d,1H), 5.17 (s,1H), 5.52 (m,1H), 7.21 (m,4H),
N-(2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl)-N'-(2-(3-(5- methyl-6-methoxycarbonyl-7-cyclohexyl-8-ethoxycarbo- nyl), 1H NMR (200 MHz) δ 0.98 (m,6H), 1.25 (t,3H), 1.49
(m,5H), 1.94 (m,8H), 2.35 (m,2H), 2.6 (s,3H), 3.54 (m, 14H) , 3 . 68 ( s,1H), 3 .85 (m, 2H) , 3 .91 ( d,1H), 4 . 13 (m, 4H) , 4 . 19 ( d,1H), 4 . 64 ( d,1H), 5.87 ( s,1H), 5.51 (m,1H),
N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5-me- thyl-6-methoxycarbonyl-7-cyclohexyl-8-ethoxycarbonyl),
1H NMR (200 MHz) δ 0.98 (m,12H), 1.05 (t,6H), 1.25 (t,3H), 1.51 (m,5H), 2.35 (m,2H), 2.61 (s,3H), 2.98 (q,4H), 3.53 (m,10H), 3.66 (s,3H), 3.84 (m,2H), 3.91 (d,1H), 4.14 (m,4H), 4.22 (d,1H), 4.66 (d,1H), 5.51 (m,1H), 6.06 (d,1H), 7.1 (d,1H),
N-(4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-N'-(2- ( 3-(5-methyl-6-methoxycarbonyl-7-cyclohexyl-8-ethoxy- carbonyl), 1H NMR (200 MHz) δ 1.01 (m,6H), 1.25 (t,3H), 1.49 (m,5H), 1.94 (m,8H), 2.35 (m,2H), 2.6 (s,3H), 3.53 (m,14H), 3.65 (s,3H), 3.84 (m,2H), 3.91 (d,1H), 4.13 (m,4H), 4.19 (d,1H), 4.64 (d,1H), 5.52 (m,1H),
N-(2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl)-N'-(2-(3-(5- methyl-6-allyloxycarbonyl-7-(3-nitrophenyl)-8-ethoxy- carbonyl), 1H NMR (200 MHz) δ 1.25 (t,3H), 1.93 (m,8H), 2.31 (m,2H), 2.59 (s,3H), 3.55 (m,14H), 3.85 (m,2H), 4.13 (m,4H), 4.2 (d,1H), 4.61 (m,2H), 4.65 (d,1H), 4.84 (s,1H), 5.22 (m,3H), 5.49 (m,1H), 5.9 (m,1H), 7.41 (t,1H), 7.61 (d,1H), 8.05 (m,2H),
N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5-methyl-6-allyloxycarbonyl-7-(3-nitrophenyl)-8-ethoxycar- bonyl), 1H NMR (200 MHz) δ 0.97 (t,6H), 1.04 (t,6H), 1.25 (t,3H), 2.33 (m,2H), 2.61 (s,3H), 2.98 (q,4H), 3.52 (m,10H), 3.84 (m,2H), 4.13 (m,4H), 4.21 (d,1H), 4.61 (m,2H), 4.66 (d,1H), 5.22 (m,3H), 5.49 (m,1H), 5.9 (m,1H), 6.06 (d,1H), 7.1 (d,1H), 7.42 (t,1H), 7.6 (d,1H), 8.05 (m,2H), N-(4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-N'-(2- (3-(5-methyl-6-allyloxycarbonyl-7-(3-nitrophenyl)-8- ethoxycarbonyl), 1H NMR (200 MHz) δ 1.25 (t,3H), 1.94 (m,8H), 2.33 (m,2H), 2.59 (s,3H), 3.53 (m,14H), 3.84 (m,2H), 4.14 (m,4H), 4.19 (d,1H), 4.62 (m,2H), 4.64 (d,1H), 5.22 (m,3H), 5.49 (m,1H), 5.91 (m,1H), 7.42 (t,1H), 7.61 (d,1H), 8.05 (m,2H),
N-(2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl)-N'-(2-(3-(5- methyl-6-allyloxycarbonyl-7-(3-chlorophenyl)-8-ethoxy- carbonyl), 1H NMR (200 MHz) δ 1.25 (t,3H), 1.93 (m,8H), 2.33 (m,2H), 2.6 (s,3H), 3.54 (m,14H), 3.83 (m,2H), 4.13 (m,4H), 4.2 (d,1H), 4.6 (m,2H), 4.65 (d,1H), 4.86 (s,1H), 5.21 (m,3H), 5.48 (m,1H), 5.89 (m,1H), 7.21 (m,4H),
N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5-me- thyl-6-allyloxycarbonyl-7-(3-chlorophenyl)-8-ethoxycar- bonyl), 1H NMR (200 MHz) δ 0.96 (t,6H), 1.03 (t,6H), 1.25 (t,3H), 2.33 (m,2H), 2.58 (s,3H), 2.98 (q,4H), 3.51 (m,10H), 3.83 (m,2H), 4.13 (m,4H), 4.19 (d,1H), 4.62 (m,2H), 4.64 (d,1H), 5.22 (m,3H), 5.48 (m,1H), 5.89 (m,1H), 6.06 (d,1H), 7.11 (d,1H), 7.23 (m,4H), N-(4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-N'-(2- (3-(5-methyl-6-allyloxycarbonyl-7-(3-chlorophenyl)-8- ethoxycarbonyl), 1H NMR (200 MHz) δ 1.26 (t,3H), 1.93 (m,8H), 2.33 (m,2H), 2.57 (s,3H), 3.53 (m,14H), 3.84 (m,2H), 4.14 (m,4H), 4.21 (d,1H), 4.62 (m,2H), 4.66 (d,1H), 5.23 (m,3H), 5.48 (m,1H), 5.88 (m,1H), 7.22 (m,4H),
N-(2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl)-N'-(2-(3-(5- methyl-6-allyloxycarbonyl-7-cyclohexyl-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 0.98 (m,6H), 1.26 (t,3H), 1.51 (m,5H), 1.94 (m,8H), 2.33 (m,2H), 2.59 (s,1H), 3.53 (m,14H), 3.83 (m,2H), 3.91 (d,1H), 4.13 (m,4H), 4.19 (d,1H), 4.61 (m,2H), 4.64 (d,1H), 4.86 (s,1H), 5.22 (m,2H), 5.48 (m,1H), 5.88 (m,1H),
N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5-me- thyl-6-allyloxycarbonyl-7-cyclohexyl-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 1.01 (m,12H), 1.05 (t,6H), 1.26 (t,3H), 1.49 (m,5H), 2.33 (m,2H), 2.59 (s,3H), 2.97 (q,4H), 3.52 (m,10H), 3.83 (m,2H), 3.9 (d,1H), 4.12 (m,4H), 4.2 (d,1H), 4.6 (m,2H), 4.65 (d,1H), 5.21
(m,2H), 5.48 (m,1H), 5.9 (m,1H), 6.06 (d,1H), 7.11 (d,1H),
N-(4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-N'-(2- (3-(5-methyl-6-allyloxycarbonyl-7-cyclohexyl-8-ethoxy- carbonyl), 1H NMR (200 MHz) δ 0.98 (m,6H), 1.25 (t,3H),
1.49 (m,5H), 1.93 (m,8H), 2.33 (m,2H), 2.59 (s,3H), 3.55 (m,14H), 3.83 (m,2H), 3.89 (d,1H), 4.13 (m,4H), 4.19 (d,1H), 4.59 (m,2H), 4.64 (d,lH), 5.21 (m,2H), 5.48 (m,1H), 5.87 (m,1H).
EXAMPLE 3
a) A solution of 1 g of N-[2,6-bis(pyrrolidin-1- yl)pyrimidin-4-yl]-N'-[2-(3-(5-methyl-6-allyloxycarbo- nyl-7-(3-nitrophenyl)-8-ethoxycarbonyl)[3H,7H]thiazo- le[3,4-a]pyridinyl)ethoxythiocarbonyl]piperazine in 8 ml of dioxane is added with 0.25 g of 10% Pd/C, 0.37 g of ammonium formate and 15 mg of triphenylphosphine, under stirring and inert gas atmosphere, then the reaction mixture is refluxed for 6 hours. After that, the reaction mixture is filtered through celite, diluted with AcOEt (10 ml) and washed repeatedly with water
(3x5 ml). The resulting organic phase is dried over so dium sulfate and solvent is evaporated off under reduced pressure, to obtain a residue (0.9 g) which is purified by silica gel chromatography (30 g silica; eluent Hexane/AcOEt 6/4). 0.8 g of N-[2,6-bis(pyr- rolidin-1-yl)pyrimidin-4-yl]-N'-[2-(3-(5-methyl-6-car- boxy-7-(3-nitrophenyl)-8-ethoxycarbonyl)[3H,7H]thiazo- le[3,4-a]pyridinyl)ethoxythiocarbonyl]piperazine are obtained,
b) A solution of 0.8 g of N-[2,6-bis(pyrrolidin-1- yl)pyrimidin-4-yl]-N'-[2-(3-(5-methyl-6-carboxy-7-(3- nitrophenyl)-8-ethoxycarbonyl)[3H,7H]thiazole[3,4-a]py- ridinyl)ethoxythiocarbonyl]piperazine in 5 ml of THF is added with 0.185 g of carbonyldiimidazole, under stirring and inert gas atmosphere. After 3 hours, the reaction mixture is added with 0.65 ml of 2-(N-pyrrolidin)ethylamine and stirring is continued for 5 more hours, then the mixture is diluted with 15 ml of water and extracted with AcOEt (3x5 ml). The combined organic extracts are washed with water, dried over sodium sul- fate and solvent is evaporated off under reduced pressure. The residue (1 g) is purified by silica gel chromatography (30 g silica; eluent Hexane/AcOEt 8/2) to give 0.82 g of N-[2,6-bis(pyrrolidin-1-yl)pyrimidin-4- yl]-N'-[2-(3-(5-methyl-6-(2-(N-pyrrolidin)ethylamino- carbonyl)-7-(3-nitrophenyl)-8-ethoxycarbonyl)[3H,7H]- thiazole[3,4-a]pyridinyl)ethoxythiocarbonyl]piperazine, 1H NMR (200 MHz) δ 1.25 (t,3H), 1.84 (m,4H), 1.95 (m,8H), 2.33 (m,2H), 2.59 (s,3H), 2.8 (m,6H), 3.51 (m,16H), 3.84 (m,2H), 4.13 (m,4H), 4.19 (d,1H), 4.64 (d,1H), 4.84 (S,1H), 5.21 (s,1H), 5.48 (m,1H), 7.2 (b,1H), 7.41 (t,1H), 7.6 (d,1H), 8.03 (m,2H). EXAMPLE 4
Following the procedure described in example 1, starting from the (6-allyloxycarbonyl)[3H,7H]thiazole- [3,4-a]pyridines described in example 2, the following (6-(2-(N-pyrrolidin)ethylaminocarbonyl)[3H,7H]thiazole- [3,4-a]pyridinyl)ethoxythiocarbonyl)piperazines are obtained:
N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5-methyl-7-(3-nitrophenyl)-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 0.98 (t,6H), 1.03 (t,6H), 1.26 (t,3H), 1.85 (m,4H), 2.33 (m,2H), 2.59 (s,3H), 2.85 (m,10H), 3.51 (m,12H), 3.83 (m,2H), 4.13 (m,4H), 4.19 (d,1H), 4.64 (d,1H), 5.19 (s.lH). 5.5 (m,1H), 6.07 (d,1H), 7.11 (d,1H), 7.18 (b,1H), 7.41 (t,1H), 7.6 (d,1H), 8.03 (m,2H),
N-(4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-N'-(2- (3-(5-methyl-7-(3-nitrophenyl)-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 1.26 (t,3H), 1.84 (m,4H), 1.96 (m,8H), 2.33 (m,2H), 2.58 (s,3H), 2.81 (m,6H), 3.52 (m,16H), 3.83 (m,2H), 4.11 (m,4H), 4.18 (d,1H), 4.63 (d,1H), 5.19 (s,1H), 5.5 (m,1H), 7.15 (b,1H), 7.42 (t,1H), 7.59 (d,1H), 8.05 (m,2H),
N-(2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl)-N'-(2-(3-(5- methyl-7-(3-chlorophenyl)-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 1.26 (t,3H), 1.84 (m,4H), 1.95 (m,8H), 2.35 (m,2H), 2.59 (s,3H), 2.82 (m,6H), 3.52 (m,16H), 3.83 (m,2H), 4.13 (m,4H), 4.19 (d,1H), 4.64 (d,1H), 4.86 (s,1H), 5.18 (s,1H), 5.48 (m,1H), 7.23 (m,5H),
N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5-me- thyl-7-(3-chlorophenyl)-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 0.96 (t,6H), 1.04 (t,6H), 1.26 (t,3H), 1.83 (m,4H), 2.33 (m,2H), 2.59 (s,3H), 2.79 (m,6H), 2.99 (q,4H), 3.51 (m,12H), 3.83 (m,2H), 4.13 (m,4H), 4.21 (d,1H), 4.66 (d,1H), 5.21 (s,1H), 5.48 (m,1H), 6.06 (d,1H), 7.11 (d,1H), 7.23 (m,5H),
N-(4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-N'-(2-
(3-(5-methy1-7-(3-chlorophenyl)-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 1.25 (t,3H), 1.84 (m,4H), 1.95 (m,8H), 2.33 (m,2H), 2.59 (s,3H), 2.8 (m,6H), 3.5 (m,16H), 3.83 (m,2H), 4.15 (m,4H), 4.2 (d,1H), 4.65 (d,1H), 5.21 (s,1H), 5.5 (m,1H), 7.23 (m,5H),
N-(2,6-bis(pyrrolidin-1-yl)pyrimidin-4-yl)-N'-(2-(3-(5- methyl-7-cyclohexyl-8-ethoxycarbonyl), 1H NMR (200 MHz) £θ.99 (m,6H), 1.26 (t,3H), 1.51 (m,5H), 1.84 (m,4H), 1.95 (m,8H), 2.33 (m,2H), 2.6 (s,3H) , 2.81 (m,6H), 3.51 (m,16H), 3.83 (m,2H), 3.91 (d,1H), 4.13 (m,4H), 4.19
(d,1H), 4.64 (d,1H), 4.86 (s,1H), 5.5 (m,1H), 7.2 (b,1H),
N-(3,6-bis(diethylamino)pyridin-2-yl)-N'-(2-(3-(5-me- thyl-7-cyclohexyl-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 1 (m,12H), 1.05 (t,6H), 1.25 (t,3H), 1.5 (m,5H), 1.83 (m,4H), 2.33 (m,2H), 2.59 (s,3H), 2.8 (m,6H), 2.98 (q,4H), 3.51 (m,12H), 3.83 (m,2H), 3.91 (d,1H), 4.13 (m,4H), 4.2 (d,1H), 4.65 (d,1H), 5.48 (m,1H), 6.06 (d,1H), 7.1 (d,1H), 7.16 (b,1H),
N-(4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-N'-(2-
(3-(5-methyl-7-cyclohexyl-8-ethoxycarbonyl), 1H NMR (200 MHz) δ 0.98 (m,6H), 1.25 (t,3H), 1.51 (m,5H), 1.83 (m,4H), 1.94 (m,8H), 2.34 (m,2H), 2.59 (s,3H), 2.8 (m,6H), 3.51 (m,16H), 3.83 (m,2H), 3.9 (d,1H), 4.13 (m,4H), 4.19 (d,1H), 4.64 (d,1H), 5.5 (m,1H), 7.2 (b,1H).

Claims

Compounds of formula (I):
Figure imgf000024_0001
wherein:
R is (C1-C4) alkyl;
is free or salified carboxy group, an alkoxycarbonyl or cyano group or a group of formula -CONH(CH2)q-NRaRb, wherein q is an integer from 2 to 4; Ra is hydrogen, C1-C6 alkyl, benzyl; Rb is hydrogen or C1-C6 alkyl, or Ra and Rb, together with the nitrogen atom, form a pyrrolidino, piperidino, morpholino, 4- thiomorpholino, (C1-C4)alkylpiperazino group;
R2 is a (C3-C7)cycloalkyl group, α , β or α-pyridyl, optionally substituted phenyl or a bicyclic ring in which a benzene ring is fused to a 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, S and N, said bicyclic ring being linked through the benzene ring;
R3 is a free or salified carboxy group or an alkoxycarbonyl group;
D is a 5- or 6-membered heterocycle with 1-3 nitrogen atoms, optionally substituted with 1 or 2 amino, mono- (C1-C6)alkylamino, mono-( C3 -C7)alkenyl or mono-(C3- C7)alkynylamino, di-(C1-C6)alkylamino, (C1-C6) alkyl (C3- C7)alkenylamino, piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl groups;
and the pharmaceutically acceptable salts, single enantiomers, racemates, diastereomers and mixtures thereof.
2. Compounds according to claim 1, wherein R2 is selected from phenyl groups bearing the following substituents: 2-chloro-, 3-chloro-, 4-chloro-, 2 , 3-dichloro-, 2-fluoro-, 2-fluoro-3-chloro-, 2-nitro-, 3-nitro-, 3- nitro-4-phenoxy-, 4-nitro-, 4-nitro-3-phenoxy-, 2-tri- fluoromethyl-, 3-trifluoromethyl-, 3-cyano-, 3-methoxy- , 2-amino-, 3-amino-, 4-amino-, 2-methanesulfonamido-, 3-methanesulfonamido-, 4-methanesulfonamido-, 3-metha- nesulfonamido-4-phenoxy-, 4-methanesulfonamido-3-phe- noxy-, 4-fluoro-2,3-dichloro-, 3-carboxy-4-hydroxy-, 3- hydroxy-4-carboxy- and the combinations thereof or from benzo-1,3-dioxolane-4-yl, 1,4-benzodioxolane-6-yl, 1,4- benzodioxolane-5-yl, benzofuran-4-yl, benzofurazan-4-yl groups.
3. Compounds according to any one of the preceding claims wherein D is selected from the group consisting of pyridin-2-yl, [2,6-bis(diethylamino)pyrimidin-4-yl], [2,6-bis(2-propenylamino)pyrimidin-4-yl], [2,6-bis(amino)pyrimidin-4-yl], [ 2 ,6-bis(pyrrolidin-1-yl)pyrimidin4-yl], [4,6-bis(2-propenylamino)-1,3,5-triazin-2-yl], [4,6-bis(diethylamino)-1,3,5-triazin-2-yl], [4,6-bis- (pyrrolidin-1-yl)-1,3,5-triazin-2-yl], [3,6-bis(die- thylamino)pyridin-2-yl], [3,6-bis(pyrrolidin-1-yl)pyridin-2-yl], [3,6-bis(2-propenylamino)pyridin-2-yl].
4. Compounds according to any one of the preceding claims wherein R1 and R3 are both alkoxycarbonyl, or R1 is a CONH(CH2)q-NRaRb group, with q, Ra and Rb as defined above, R2 is as defined above, R is methyl.
5. Pharmaceutical compositions containing one or more compounds of formula (I) in a mixture with suitable excipients.
6. The use of compounds of formula (I) for the preparation of a medicament having antiasthmatic and antiinflammatory activities.
PCT/EP1992/002784 1991-12-06 1992-12-02 [3H,7H]THIAZOLE[3,4-a]PYRIDINES HAVING ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIVITIES ON THE RESPIRATORY TRACT WO1993011134A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI913269A IT1252626B (en) 1991-12-06 1991-12-06 ¬3H, 7H | THIAZOL ¬3.4A | PYRIDINS WITH ANTI-ASMATIC AND ANTI-INFLAMMATORY ACTIVITIES OF THE AERIAL ROUTES
ITMI91A003269 1991-12-06

Publications (1)

Publication Number Publication Date
WO1993011134A1 true WO1993011134A1 (en) 1993-06-10

Family

ID=11361270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1992/002784 WO1993011134A1 (en) 1991-12-06 1992-12-02 [3H,7H]THIAZOLE[3,4-a]PYRIDINES HAVING ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIVITIES ON THE RESPIRATORY TRACT

Country Status (4)

Country Link
AU (1) AU3084292A (en)
IT (1) IT1252626B (en)
TW (1) TW212801B (en)
WO (1) WO1993011134A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2210633A1 (en) * 1972-03-06 1973-09-20 Bayer Ag NEW BRIDGE HEAD HETEROCYCLES, METHODS OF MANUFACTURING AND USING THEM AS A DRUG
WO1987000836A1 (en) * 1985-08-06 1987-02-12 Boehringer Biochemia Robin S.P.A. Pharmaceutically active 2-thiomethyl-substituted-1,4-dihydropyridines
WO1991018906A1 (en) * 1990-06-08 1991-12-12 Boehringer Mannheim Italia S.P.A. [3H,7H]THIAZOLO[3,4-a]PYRIDINES WITH ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIONS ON THE RESPIRATORY TRACT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2210633A1 (en) * 1972-03-06 1973-09-20 Bayer Ag NEW BRIDGE HEAD HETEROCYCLES, METHODS OF MANUFACTURING AND USING THEM AS A DRUG
WO1987000836A1 (en) * 1985-08-06 1987-02-12 Boehringer Biochemia Robin S.P.A. Pharmaceutically active 2-thiomethyl-substituted-1,4-dihydropyridines
WO1991018906A1 (en) * 1990-06-08 1991-12-12 Boehringer Mannheim Italia S.P.A. [3H,7H]THIAZOLO[3,4-a]PYRIDINES WITH ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIONS ON THE RESPIRATORY TRACT

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY. vol. 34, no. 7, July 1991, WASHINGTON US pages 2248 - 2260 I. SIRCAR ET AL. 'Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-((phenylsul fonyl)methyl)-4-aryl-3-pyridine-carboxylat e and analogues. Synthesis and structure-activity relationships' *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them

Also Published As

Publication number Publication date
ITMI913269A1 (en) 1993-06-06
TW212801B (en) 1993-09-11
AU3084292A (en) 1993-06-28
IT1252626B (en) 1995-06-19
ITMI913269A0 (en) 1991-12-06

Similar Documents

Publication Publication Date Title
US5424428A (en) (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]pr
ES2750236T3 (en) Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
US4686228A (en) Quinoline therapeutic agents
ES2730942T3 (en) Triazolopyridine derivatives as modulators of TNF activity
JPH07502014A (en) 2-Amino-4-aryl-thiazoles with anti-asthmatic, anti-inflammatory activity on the respiratory tract
JPH0568476B2 (en)
JP3169188B2 (en) Carbamic acid derivative and method for producing the same
WO1993011134A1 (en) [3H,7H]THIAZOLE[3,4-a]PYRIDINES HAVING ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIVITIES ON THE RESPIRATORY TRACT
CA2048959C (en) 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
JPH08283262A (en) 4-indolylpiperazinyl derivative
JPH07252260A (en) Novel thienothiazine derivative, method for producing the same and method for using the same
US5270309A (en) Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
CA2084669C (en) [3h,7h]thiazolo[3,4-a]pyridines with antiasthmatic and a antiinflammatory actions on the respiratory tract
DE60005349T2 (en) DITHIEPINO [6,5-B] PYRIDINE AND THESE COMPOSITIONS AND METHOD USED
US5464844A (en) [3H,7H]thiazole[3,4-a]pyridines having antiasthmatic and antiinflammatory activities on the respiratory tract
KR101646093B1 (en) Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
JP3165769B2 (en) Xanthine derivative
JPH03294277A (en) piperidine derivatives
JPS63152381A (en) Histamine h1 antagonist
TWI261593B (en) Dithiepino[6,5-b]pyridines, and related compositions and methods
JP2003516990A (en) Saccharin derivatives as orally active elastase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO NZ PL RO RU SD UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA